Flexion Therapeutics, Inc. (NASDAQ:FLXN) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On May4, 2017, Flexion Therapeutics, Inc. issued a press release
announcing its financial results for the quarter ended March31,
2017 and also hosted a conference call to discuss the financial
results. A copy of the press release and call transcript are
attached hereto as Exhibits 99.1 and 99.2, respectively.
The information in this Item 2.02 and Exhibits 99.1 and 99.2
hereto is being furnished and shall not be deemed filed for the
purposes of Section18 of the Securities Exchange Act of 1934, as
amended, or the Exchange Act, or otherwise subject to the
liabilities of that section, nor shall they be deemed
incorporated by reference into any filing under the Exchange Act
or the Securities Act of 1933, as amended, or the Securities Act,
except as expressly set forth by specific reference in such
filing.
| Item9.01 | Financial Statements and Exhibits. |
(d)Exhibits
|
Exhibit No. |
Description |
|
| 99.1 | Press Release of Flexion Therapeutics, Inc. dated May4, 2017. | |
| 99.2 |
Conference Call Transcript of Flexion Therapeutics, Inc. dated May 4, 2017. |
About Flexion Therapeutics, Inc. (NASDAQ:FLXN)
Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta. Flexion Therapeutics, Inc. (NASDAQ:FLXN) Recent Trading Information
Flexion Therapeutics, Inc. (NASDAQ:FLXN) closed its last trading session down -0.86 at 18.57 with 1,202,786 shares trading hands.